SecBot SecBot
SECBOTREPLAY Home › Report › LFCR

LFCR · $6.28 + CVR take-private

LIFECORE BIOMEDICAL, INC. \DE\ · DEFM14A filed Nov 13, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 6/10

DEFM14A filed Nov 13, 2026 at 16:01 ET

Lifecore Biomedical is being acquired by affiliates of Webster Equity Partners for $6.28 per share in cash plus one contingent value right (CVR) per share. The deal values the company at approximately $238 million in equity consideration (based on 37.9M common shares outstanding). The board unanimously recommends approval, and holders of ~27.4% of voting power have already agreed to vote in favor. The special meeting is scheduled for December 23, 2026.

  • Merger consideration: $6.28 per share in cash plus one CVR per share
  • Series A Preferred Stock holders receive Conversion Amount ($1,000/share + $18.125 accrued dividends as of Sept 27, 2026) plus CVRs
  • Total funds needed at closing: approximately $550 million, funded by $400M equity commitment and $150M debt commitment ($115M term loans + $30M revolver + $35M Alcon term loan)
  • HSR waiting period terminated early on November 4, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access